Management of tuberculous pleuritis: can we do better?
Management of patients with tuberculous pleuritis can be improved by establishing early diagnosis accurately, administering effective chemotherapy, and close monitoring of progress for early detection and prompt management of severe pleural inflammation in the hope of preventing or reducing subsequent residual pleural fibrosis. In addition to the conventional diagnostic tools, chemical markers, especially pleural fluid adenosine deaminase and interferon-gamma levels and new microbiological tests such as polymerase chain reaction and BACTEC culture of pleural biopsy specimens for Mycobacterium tuberculosis, can increase the diagnostic yield for tuberculous pleuritis. Indicators of the severity of pleural inflammation, including high pleural fluid tumour necrosis factor-alpha and lysozyme levels, and low pleural fluid glucose and pH, can help to predict residual pleural fibrosis. It is likely that patients will require surgery: (i) complete drainage of pleural fluid for prevention; and (ii) pleurectomy for the treatment of residual pleural fibrosis.
Wong
Poon-Chuen
PC
Tuberculosis & Chest Unit, Grantham Hospital, Aberdeen, Hong Kong, China. wongpc@ha.org.hk
D000904:Antibiotics, Antitubercular / Q000627:therapeutic use; D016207:Cytokines; D042241:Early Diagnosis; D006801:Humans; D016896:Treatment Outcome; D014396:Tuberculosis, Pleural / Q000175:diagnosis* / Q000188:drug therapy*
D000904:Antibiotics, Antitubercular; D016207:Cytokines